CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins80% CONFIDENCEOverall confidence: 80%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterThe Business Wire[4] copy of GSK's[1] release carries the 16 December 2025 stamp in its URL (20251216) and The Pharma Letter[3], dated 18 December, says GSK 'yesterday announced' the approval.
On 16 December 2025 the US FDA approved Exdensur (depemokimab-ulaa) as add-on maintenance treatment for severe eosinophilic asthma in people aged 12 and over, dosed twice a year.
1.00